Moderna’s COVID-19 Vaccine Potential Taking Shape [Yahoo! Finance News]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance News
COVID-19 has put the world in a chokehold, but one biotech name appears to be well on its way to delivering a match-winning knockout.On Tuesday, Moderna MRNAWeighing in for Chardan Capital, analystGeulah LivshitsIt should be noted that the KOLs pointed out there’s a high level of uncertainty when it comes to SARS-CoV-2 immunity.“If...immunity is durable or recovered patients only experience mild disease upon re-infection, the long-term need for a SARS-CoV-2 vaccine could be limited, and the majority of commercial potential if any) could come from stockpiling in 2021-22. We believe Moderna is relatively well-positioned in either scenario if mRNA-1273 shows efficacy) given the company's accelerated clinical timeline,” Livshits explained.As a result, the analyst kept a Buy rating and $40 price target on the stock. To watch Livshits’ track record,click hereMeanwhile, Oppenheimer’sHartaj Singh“While mRNA-1273's nearer-term impact to the investment thesis is significant, we remain bullish o
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results [Yahoo! Finance]Yahoo! Finance
- The 20 stocks most shorted by hedge funds [Seeking Alpha]Seeking Alpha
- Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "sector perform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 1/12/26 - Form 8-K
- 1/6/26 - Form 4
- 1/5/26 - Form 8-K
- MRNA's page on the SEC website